Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 3/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881883 | 1.00 | GPR119 (0.50) | GPR119NAMPTSTSTGFBR1MMP1 | |
| SCHEMBL26966945 | 0.90 | GPR119 (0.47) | GPR119NAMPTSTSTGFBR1MMP1 | |
| SCHEMBL21426007 | 0.89 | MMP13 (0.53) | GPR119NAMPTSTS | |
| SCHEMBL21426003 | 0.89 | MMP13 (0.53) | GPR119NAMPTSTS | |
| SCHEMBL6880661 | 0.89 | NAMPT (0.48) | GPR119NAMPTSTSTGFBR1 | |
| SCHEMBL21426010 | 0.83 | GPR119 (0.52) | GPR119NAMPTSTSMMP1MMP3 | |
| SCHEMBL21426002 | 0.83 | GPR119 (0.52) | GPR119NAMPTSTSMMP1MMP3 | |
| SCHEMBL23546383 | 0.82 | GPR119 (0.60) | GPR119NAMPTSTS | |
| SCHEMBL4768567 | 0.82 | GPR119 (0.68) | GPR119NAMPT | |
| SCHEMBL21426005 | 0.82 | MMP13 (0.49) | GPR119NAMPTSTSMMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278728-B1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| EP-1278728-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| US-6451819-B2 | PYRROLIDINE-3-YL-SULFANYL, OR SUFONYL OR SUFINYL DERIVATIVES USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | HOFFMANN-LA ROCHE INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | GRIN1, GRM1, GRIN2B | GPR119 418/4885NAMPT 4025/4885STS 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.